The genetic basis of variability in drug responses

被引:183
作者
Roden, DM
George, AL
机构
[1] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA
关键词
D O I
10.1038/nrd705
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
It is almost axiomatic that patients vary widely in their beneficial responses to drug therapy, and serious and apparently unpredictable adverse drug reactions continue to be a major public health problem. Here, we discuss the concept that genetic variants might determine much of this variability in drug response, and propose an algorithm to enable further evaluation of the benefits and pitfalls of this enticing possibility.
引用
收藏
页码:37 / 44
页数:8
相关论文
共 81 条
[1]   Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J].
Aithal, GP ;
Day, CP ;
Kesteven, PJL ;
Daly, AK .
LANCET, 1999, 353 (9154) :717-719
[2]  
Ando Y, 2000, CANCER RES, V60, P6921
[3]  
BEUTLER E, 1955, J LAB CLIN MED, V45, P40
[4]  
BONICKE R, 1957, NATURWISSENSCHAFTEN, V44, P314
[5]   Postmarketing surveillance and adverse drug reactions - Current perspectives and future needs [J].
Brewer, T ;
Colditz, GA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (09) :824-829
[6]   ROLE OF P450IID6, THE TARGET OF THE SPARTEINE-DEBRISOQUIN OXIDATION POLYMORPHISM, IN THE METABOLISM OF IMIPRAMINE [J].
BROSEN, K ;
ZEUGIN, T ;
MEYER, UA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 49 (06) :609-617
[7]   Recurrent angiotensin-converting enzyme inhibitor-associated angioedema [J].
Brown, NJ ;
Snowden, M ;
Griffin, MR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 278 (03) :232-233
[8]   Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema [J].
Brown, NJ ;
Ray, WA ;
Snowden, M ;
Griffin, MR .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (01) :8-13
[9]  
Caraco Y, 1999, J PHARMACOL EXP THER, V290, P413
[10]   Adverse drug events in hospitalized patients - Excess length of stay, extra costs, and attributable mortality [J].
Classen, DC ;
Pestotnik, SL ;
Evans, RS ;
Lloyd, JF ;
Burke, JP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (04) :301-306